Use of selective Beta‐3 adrenergic receptor agonists to treat pulmonary hypertension
Currently, there is a lack of treatments for pulmonary hypertension. Advances in the development of new pharmacological therapies, have focused on idiopathic pulmonary hypertension, the least frequent subgroup (prevalence of 6 cases per million people). In this subgroup the first line treatment is calcium‐antagonists, which are only effective over the long term in 1% of the cases. Other treatments using vasodilators, such as prostaglandins, 5‐phosphodiestarase inhibitors or endothelin receptor antagonists, provide benefits in a higher percentage of patients, although their clinical and hemodynamic effect is small (mean PAP reduction of 2‐10%). In addition, these treatments have not proven consistent efficiency in pulmonary hypertension secondary to a left cardiac pathology (the most frequent), nor in any of the remaining pulmonary hypertension groups in general.
Therefore, the problem of treating pulmonary hypertension is still far from being satisfactorily resolved and the need to develop new therapies still exists. There has been little research on β3‐adrenergic receptors in the field of cardiovascular diseases. Stimulation of these receptors is associated with the production of nitric oxide and the relaxation of vascular tone. The authors of the present invention have found that selective stimulation of beta‐3 adrenergic receptors has a beneficial effect in pulmonary hypertension.
We describe a novel effective treatment for pulmonary hypertension of different aetiology, both chronic and acute.
- Tecnología sanitaria:
- Biotecnología y Diagnóstico Molecular (proteómica, genómica, etc...)